Nisha Shariff

Nisha Shariff

Auto-generated profile, based on publicly available information

Nisha Shariff

University (MCO) Malaya Medical Centre, Kuala Lumpur, Malaysia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2025 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
NSNisha Shariff
Nisha Shariff
ALAnthony Lausch
Anthony Lausch
EBEric Bouffet
Eric Bouffet
DTDerek S Tsang
Derek S Tsang
Purpose: Re‐irradiation (RT2) for children with diffuse intrinsic pontine glioma (DIPG) is increasingly used upon recurrence; however, limited data are available for evaluating additional courses of radiotherapy (RT) for DIPG. The purpose of this case series was to report our institutional experience in treating patients with recurrent DIPG with three (RT3) or four (RT4) courses of RT.Material and Methods: A retrospective study of all children with DIPG treated with RT3 or RT4 at a single institution was performed. Medical records were reviewed, and composite dosimetry across all delivered courses of RT was reconstructed. All patients received conventionally fractionated photon RT at 1.8–2 Gy per day, with RT3 or RT4 dose prescriptions ranging 18–21.6 Gy in 10–12 fractions to the brainstem.Results: Five patients were identified; four received three courses of RT while one received four to the brainstem. Median survival from the last course of radiation to death was 4 months; median survival from the first course of RT was 26 months. The median cumulative brainstem D0.03cc for all courses of radiation was 104 Gy (interquartile range: 102–112 Gy). The median time from RT2 to RT3 was 8 months, with partial neurologic recovery (80%) or stable symptoms (20%) after RT3. Radiological appearance of tumor or brainstem necrosis was reported in two patients after RT3 (40%).Conclusions: A third course of RT may be carefully considered as a treatment option for selected children with recurrent DIPG to provide palliation of neurologic symptoms.

1 January 2026 in Advances in Radiation Oncology
Verified
Journal Article
Open access
HNHoong Hoong Ng
Hoong Hoong Ng
MRMunira Mohd Rejab
Munira Mohd Rejab
DLDavid Lee
David Lee
XCXin Yee Chiew
Xin Yee Chiew
SRSyaza Ab Rahman
Syaza Ab Rahman
NSNisha Shariff
Nisha Shariff
Total body irradiation (TBI) is a critical component of conditioning therapy prior to allogeneic hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia. Our institution implemented volumetric modulated arc therapy-TBI (VMAT-TBI) in 2023, aiming to improve target conformity and organ-at-risk sparing using standard linear accelerators. This study describes our initial 2-year institutional experience with VMAT-TBI, focusing on treatment planning and delivery metrics, as well as early clinical outcomes and acute toxicities in pediatric patients. We conducted a review of 10 pediatric patients treated with VMAT-TBI at our institution from October 2023 to June 2025. All patients received myeloablative conditioning with 12 Gy in 6 fractions over 3 days, followed by intravenous etoposide preceding allogeneic hematopoietic stem cell transplantation. Data collected included treatment planning parameters, planning duration, delivery times, overall survival, relapse-free survival, and acute toxicities. Treatment plans achieved robust target coverage (V 100 > 90%) and met organ-at-risk constraints, with mean lung, kidney, and lens doses of 8.8 Gy, 8.7 Gy, and 8.5 Gy, respectively. Mean beam-on time per fraction was 21.3 minutes, and in-room time was 77 minutes. Image guided verification showed that online translation was within 3 mm and <1° rotation. The median follow-up was 19 months, with 1-year overall survival and relapse-free survival rates of 90%. Nonrelapse mortality at 1 year was 10%. The most common acute toxicity was mucositis, affecting 70% of patients (grades 2-3 in 40%), with a median onset of 2 days. Gastrointestinal toxicities, including vomiting (50%) and diarrhea (40%), occurred early, with a median onset of 2-3 days. Our early institutional experience demonstrates that VMAT-TBI is safe, feasible, and effective in pediatric patients, achieving excellent target coverage and acceptable acute toxicity profiles. These findings support the viability of implementing VMAT-TBI even in resource-constrained settings.

1 November 2026 in Journal of Korean Neurosurgical Society
Verified
Journal Article
Open access
PDF file
RWRu-Xin Wong
Ru-Xin Wong
KSKanjana Shotelersuk
Kanjana Shotelersuk
BJBongkot Jia-Mahasap
Bongkot Jia-Mahasap
WRWarissara Ronthong
Warissara Ronthong
JFJen-Chun Foo
Jen-Chun Foo
Jooyoung KimJooyoung Kim
Jooyoung Kim
Objective : Central nervous system germ cell tumours (CNS GCTs) are more prevalent in Asia than in Western populations. Treatment approaches remain heterogeneous across different Asian countries.Methods : Following a physical meeting of Asian specialists in Seoul in September 2024, an on-site and electronic survey was conducted among Asian specialists within the NeUro Germ cell Asia network to assess practice patterns and identify areas requiring consensus.Results : Forty-two specialists from eight Asian countries participated. Findings highlight the need for an Asian consortium to standardize management. Key variations were noted in age stratification, necessity of biopsy, tumour marker cut-offs, classification of bifocal disease and management of basal ganglia tumours, the role of chemotherapy in germinomas, and radiotherapy dose and volume for non-germinomatous germ cell tumours (NGGCTs).Conclusion : This survey identifies substantial practice variation in CNS GCT management across Asia. Priority areas requiring consensus include biopsy indications, tumour marker interpretation, age-adapted treatment strategies, the role of radiotherapy alone in adolescent and young adult germinoma, and optimisation of chemotherapy and radiotherapy approaches for NGGCT.

9 December 2025 in Medical Dosimetry
Verified
Journal Article
Closed access
MRM. Rejab
M. Rejab
NKN.F. Khairuman
N.F. Khairuman
SJS. Jagabattuni
S. Jagabattuni
DHD.A. Hizam
D.A. Hizam
NSN. Mohd Shariff
N. Mohd Shariff
ANA.H. Ng
A.H. Ng

26 May 2026 in EJC Paediatric Oncology
Verified
Journal Article
Open access
SHSean P. Hassan
Sean P. Hassan
NSNisha Shariff
Nisha Shariff
XLXuan Li
Xuan Li
YZYuan Zhong
Yuan Zhong
AMAlejandro Shiri Moreno
Alejandro Shiri Moreno
DTDerek S Tsang
Derek S Tsang